03-04-02

Express Mail Label No.: E 054297998US

Date of Deposit: February 28, 2002

Attorney Docket No. 15966-721 (Cura-221)

0300

58 2025 E

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Li et al.

SERIAL NUMBER:

09/804,014

EXAMINER:

Not Yet Assigned

FILING DATE:

March 12, 2001

ART UNIT:

1645

For:

NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

Assistant Commissioner for Patents

Washington, D.C. 20231

TRANSMITTAL LETTER

In response to the November 30, 2001 Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, transmitted herewith for filing in the present application are the following documents:

1. Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 pg.);

2. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, File Missing Parts (11 pgs.);

3. Check # 11923 for \$55.00;

4. Petition for One-Month Extension of Time (1 pg); and

5. Return Postcard.

Respectfully submitted

Ivor R. Elrifi (Reg. No./39,52

David E. Johnson (Reg. No. 41,874)

Attorneys for the Applicant c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241


TRA 1637385v1

February 28, 2002

30623
PATENT TRADEMARK OFFICE



Attorney Docket No. 15966-721 (Cura-221)







Li et al.

SERIAL NUMBER:

09/804,014

EXAMINER:

Not Yet Assigned

FILING DATE:

March 12, 2001

ART UNIT:

1645

For:

NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

Assistant Commissioner for Patents

Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

This is in response to the November 30, 2001 Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice").

Applicants believe that this Notice has been sent in error because the Application Serial Number listed on the Raw Sequence Listing Error Report and the Raw Sequence Listing attached thereto do not correspond to the Application Number of the present application. Therefore, no response to the "Notice" is believed required. A copy of the Notice and other documents are attached hereto.

A petition for extension of time is enclosed. The Commissioner is authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311,

Attorney Reference No. 15966-721 (Cura-221).

Respectfully submitted,

February 28, 2002

Ivor R. Elrifi (Reg. No. 39


David E. Johnson (Reg.) No. 41/374)

Attorneys for the Applicant MINTZ, LEVIN c/o

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/804,014

03/12/2001

Li Li

15966-721

CONFIRMATION NO. 8877

FORMALITIES LETTER

OC00000007141014

Naomi S. Biswas, Esq. Mintz, Levin, Cohn, Ferris, Glovsky and Popoeo, P.C. One Financial Center Boston, MA 02111

Date Mailed: 11/30/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of
the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as
indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a
substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content
of the sequence listing information recorded in computer readable form is identical to the written (on paper
or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR
1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE